



OPEN ACCESS

EDITED BY

Juan Xicohtencatl-Cortes,
Hospital Infantil de México
Federico Gómez, Mexico

REVIEWED BY

Angel Manjarrez-Hernandez,
National Autonomous University
of Mexico, Mexico
Miklos Fuzi,
Independent researcher, Budapest, Hungary

*CORRESPONDENCE

Azucena Mora
✉ azucena.mora@usc.es

[†]These authors have contributed
equally to this work and share
first authorship

[‡]These authors have contributed equally to
this work

RECEIVED 06 December 2023

ACCEPTED 02 February 2024

PUBLISHED 27 February 2024

CITATION

García-Meniño I, García V, Lumbreras-Iglesias P, Fernández J and Mora A (2024) Fluoroquinolone resistance in complicated urinary tract infections: association with the increased occurrence and diversity of *Escherichia coli* of clonal complex 131, together with ST1193. *Front. Cell. Infect. Microbiol.* 14:1351618. doi: 10.3389/fcimb.2024.1351618

COPYRIGHT

© 2024 García-Meniño, García, Lumbreras-Iglesias, Fernández and Mora. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](#). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Fluoroquinolone resistance in complicated urinary tract infections: association with the increased occurrence and diversity of *Escherichia coli* of clonal complex 131, together with ST1193

Isidro García-Meniño^{1,2,3†}, Vanesa García^{1,2†}, Pilar Lumbreras-Iglesias^{4,5}, Javier Fernández^{4,5,6,7,8‡} and Azucena Mora^{1,2*‡}

¹Laboratorio de Referencia de *Escherichia coli* (LREC), Dpto. de Microbiología e Parasitología, Universidade de Santiago de Compostela (USC), Lugo, Spain, ²Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain, ³Department for Biological Safety, German Federal Institute for Risk Assessment, Berlin, Germany, ⁴Servicio de Microbiología, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain, ⁵Grupo de Microbiología Traslacional, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain, ⁶Research and Innovation, Artificial Intelligence and Statistical Department, Pragmatech AI Solutions, Oviedo, Spain, ⁷CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain, ⁸Departamento de Biología Funcional, Universidad de Oviedo, Oviedo, Spain

Introduction: Urinary tract infections (UTIs) are one of the leading causes of multidrug-resistance (MDR) spread and infection-related deaths. *Escherichia coli* is by far the main causative agent. We conducted a prospective study on complicated urinary tract infections (cUTIs) i) to monitor the high-risk clones that could be compromising the therapeutic management and ii) to compare the cUTI etiology with uncomplicated infections (uUTIs) occurring in the same period and health area.

Methods: 154 non-duplicated *E. coli* recovered from cUTIs in 2020 at the Hospital Universitario Central de Asturias (Spain) constituted the study collection.

Results: Most cUTI isolates belonged to phylogroup B2 (72.1%) and met the uropathogenic (UPEC) status (69.5%) (≥ 3 of *chuA*, *fyuA*, *vat*, and *yfcV* genes). MDR was exhibited by 35.7% of the isolates, similarly to data observed in the uUTI collection. A significant difference observed in cUTI was the higher level of fluoroquinolone resistance (FQR) (47.4%), where the pandemic clonal groups B2-CC131 and B2-ST1193 (CH14-64) comprised 28% of the 154 *E. coli*, representing 52.1% of the FQR isolates. Other prevalent FQR clones were D-ST69 (CH35-27), D-ST405 (CH37-27), and B2-ST429 (CH40-20) (three isolates each). We uncovered an increased genetic and genomic diversity of the CC131: 10 different virotypes, 8 clonotypes (CH), and 2 STs. The presence of *bla*_{CTX-M-15} was determined in 12 (7.8%) isolates (all CC131), which showed 10 different core genome (cg)STs and 2 *fimH* types (*fimH*30 and *fimH*602) but the same set of chromosomal mutations conferring FQR (*gyrA* p.S83L, *gyrA* p.D87N, *parC* p.S80L,

parC p.E84V, and *parE* p.I529L). In addition, the plasmidome analysis revealed 10 different IncF formulae in CC131 genomes.

Conclusion: We proved here that non-lactose fermenting screening, together with the detection of O25b (*rfbO25b*), H4 (*fliC_{H4}*), and H5 (*fliC_{H5}*) genes, and phylogroup and clonotyping assignation, is a reasonable approach that can be easily implemented for the surveillance of emerging high-risk clones associated with FQR spread in cUTIs, such as the uncommonly reported O25b:H4-B2-ST9126-CC131 (CH1267-30). Since *E. coli* CC131 and ST1193 are also involved in the community uUTIs of this health area, interventions to eradicate these MDR clones, along with surveillance for other emerging ones, are essential for antibiotic use optimization programs.

KEYWORDS

complicated urinary tract infection (cUTI), fluoroquinolone resistance (FQR), uropathogenic *Escherichia coli* (UPEC), ST131, ST1193, ST9126

1 Introduction

Urinary tract infection (UTI) is a leading cause of community-acquired and nosocomial infections, accounting for 30%–40% of all infections treated in hospitals (Klebens et al., 2007), and a second cause of antibiotic prescription globally. In addition to their important public health burden, affecting in the USA more than 150 million individuals annually, with more than 10 million outpatient visits per year and approximately 100,000 hospital admissions, UTIs also pose a high economic impact with an estimated cost between 1.6 and 3.5 billion dollars every year (Flores-Mireles et al., 2015; MacVane et al., 2015; Aabenhus et al., 2017; Medina and Castillo-Pino, 2019; Klein and Hultgren, 2020).

The global number of deaths associated with UTI across 11 infectious syndromes and 33 bacterial pathogens is also outstanding, which accounted for an estimation of 375,106 deaths in 2019, with 14.1 deaths per 100,000 habitants only in Spain (Ikuta et al., 2022). In women, the anatomy and shorter urethra facilitate the increased susceptibility to UTIs, thus being more susceptible to suffer UTI than men. In fact, over 50% of women will develop at least one episode of UTI at some point in their lifetime, and one in three will have at least one symptomatic UTI requiring antimicrobial treatment by the age of 24 (Foxman, 2003; Aydin et al., 2015).

The clinical spectrum of UTIs comprises a heterogeneous group of conditions, differing from uncomplicated UTI (uUTI) to complicated UTI (cUTI). The uUTI is relatively frequent in healthy, premenopausal, sexually active women. On the contrary, the cUTI occurs in patients with structural abnormalities or underlying diseases, which increases the chance to progress to a severe infection (acute and/or chronic renal failure affecting the function of kidneys, and even urosepsis), requiring longer antibiotic treatments (Foxman, 2010; Gupta et al., 2011). Finally, the recurrent

UTI (rUTI) also represents an important clinical problem, where pathogen persistence in the gut microbiota, or in the bladder epithelium, causes at least nearly half of the patients getting a second infection over the course of a year (Aydin et al., 2015).

Uropathogenic *E. coli* (UPEC) is by far the main etiological agent diagnosed in all kinds of UTIs (75%–95%) (Foxman, 2014; Flores-Mireles et al., 2015; Medina and Castillo-Pino, 2019), and their health impact was estimated in approximately 120,000 deaths globally during 2019 (UTIs and pyelonephritis by UPEC), which mostly were associated with antimicrobial resistance (AMR) (Ikuta et al., 2022; Murray et al., 2022). Successful multidrug-resistant (MDR) *E. coli* lineages, also known as high-risk clones, such as ST38, ST131, ST167, ST405, ST410, ST648, or ST1193, are frequently reported in these infections (Manges et al., 2019). Together with AMR genes, they are typically carriers of a broad arsenal of extraintestinal virulence factors, which contributes to their pathogenicity. Among them, ST131 is recognized as the most successful, and ST1193 seems to follow in the footsteps of ST131 (Pitout et al., 2022). These disseminated MDR clones seem to be associated with fluoroquinolone resistance (FQR), and many are also producers of CTX-M enzymes, which seriously narrows the treatment options (Mamani et al., 2019; Flament-Simon et al., 2020a; Cummins et al., 2021; Pitout et al., 2022). As stated by other authors, evolutionary, surveillance, and clinical studies are urgently required to investigate the success of emerging clones such as ST1193 for management and prevention strategies (Pitout et al., 2022).

In a previous study, we uncovered the presence of FQR ST1193 clone implicated in 6% of the uUTI, which represents the first report in Spain in this pathology. The genomic analysis showed similar key traits than those ST1193 clones disseminated worldwide (García-Meniño et al., 2022). We aimed here i) to identify high-risk *E. coli* clones implicated in cUTI that could be compromising therapeutic management and ii) to compare the cUTI clones with uUTI

occurring in the same health area (Oviedo, Spain) and sampling period (2020) as the cUTI collection of the present study.

2 Methods

2.1 cUTI *E. coli* collection

We conducted a prospective specific study on cUTI, which included 154 non-duplicated *E. coli* isolates recovered from urine samples collected between January 2020 and March 2020. The distribution of the samples by gender was as follows: 108 women with an age range between 8 months and 97 years old, and 46 men between 3 months and 95 years old (median = 71; interquartile range, IQR = 30) (Supplementary Table S1). Uncomplicated infections, defined as those occurring in young women without any functional or anatomical anomalies in the urinary tract, were excluded from the study. The primo isolation from urine samples was performed in the Hospital Universitario Central de Asturias (HUCA) in northern Spain, whose health area covers a population of approximately 300,000 persons.

Bacterial identification was performed by matrix-assisted laser desorption/ionization–time-of-flight mass spectrometry (MALDI-TOF) (Bruker Daltonik, Bremen, Germany) after conventional culture in CHROMID™ CPS® Elite (BioMérieux, Marcy L'Étoile, France). A reliable result (at the species level) was only considered if the score obtained was higher than 2. The recovered isolates were stored at room temperature in nutrient broth (Difco) with 0.75% nutrient agar (Difco) for further characterization in the Reference Laboratory for *E. coli* (LREC-USC).

2.2 Lactose fermenting assessment

At the LREC-USC, the collection was grown by streaking on MacConkey Lactose agar (ML) (Oxoid), 37°C overnight. Non-lactose fermenting (NLF) *E. coli* were phenotypically identified by their inability to ferment lactose on the ML agar.

2.3 PCR screening of virulence traits

One single colony from the previous step was plated onto Tryptone Soy Agar (Oxoid) at 37°C overnight. Then, the bacterial growth was picked with a 1-μl inoculation loop and suspended in 600 μl of sterile Milli-Q water. Bacterial suspensions were boiled at 100°C for 5 min and then centrifuged for 2 min at 11,000 rpm to pellet bacterial debris. The supernatant was used as DNA template for the polymerase chain reaction (PCR) screening of specific virulence-encoding genes, statistically associated with higher efficiency in the colonization of the urinary tract. According to the results, the so-called status UPEC was assigned to isolates positive for ≥3 of the following marker genes (*chuA*, *fyuA*, *vat*, and *yfcV*) (Spurbeck et al., 2012) (Supplementary Table S2). The PCR screening of *rfbO25* and *fliC_{H4}*, was performed to presumptively determine the pandemic ST131 clonal group.

Additionally, the flagellar-encoding gene *fliC_{H5}* typically associated with NLF *E. coli* ST1193 was screened in those lactose negative isolates (Supplementary Table S3).

2.4 Antimicrobial susceptibility testing

Minimal inhibitory concentrations (MICs) of the 154 *E. coli* isolates were obtained using the MicroScan WalkAway System (Beckman Coulter, Brea, CA, USA) against 28 drug/drug combination: penicillins (ampicillin/amoxicillin, piperacillin, and ticarcillin); antipseudomonal penicillins + beta-lactamase inhibitors (piperacillin-tazobactam); penicillins + beta-lactamase inhibitors (amoxicillin-clavulanic acid); narrow spectrum cephalosporins (cefuroxime); broad-spectrum cephalosporins (cefepime, cefixime, cefotaxime, and ceftazidime); broad-spectrum cephalosporins + beta-lactamase inhibitors (ceftazidime-avibactam and ceftolozane-tazobactam); carbapenems (ertapenem, imipenem, and meropenem); monobactams (aztreonam); fluoroquinolones (norfloxacin, ciprofloxacin, and levofloxacin); aminoglycosides (amikacin, gentamicin, and tobramycin); glycylicyclines (tigecycline); nitrofurans (nitrofurantoin); phosphonic acids (fosfomycin); folate pathway inhibitors (trimethoprim, trimethoprim/sulfamethoxazole); and polymyxins (colistin). Additionally, colistin susceptibility was analyzed with the BMD method as described elsewhere (García-Meniño et al., 2020). Susceptibility results were interpreted according to European Committee on Antimicrobial Susceptibility Testing guidelines (EUCAST 2022). Isolates were classified as MDR if they displayed resistance to a drug of three or more of the above-mentioned antimicrobial categories (Magiorakos et al., 2012).

2.5 Screening of *mcr* and *bla* genes

The presence of *mcr* and *bla* genes was investigated by PCR, in those isolates phenotypically suspected of being colistin resistant, or extended-spectrum betalactamase (ESBL) producers, respectively (García-Meniño et al., 2021), as described elsewhere (Supplementary Table S4).

2.6 Phylogroup, clonotype, sequence type, and virotype assignment

The clonal structure of the whole collection was established by means of phylogrouping. Clonotyping was performed for those isolates that were positive for any of the following traits: FQR, O25b:H4, H5, and non-lactose fermenting (Wirth et al., 2006; Weissman et al., 2012; Clermont et al., 2013, 2019). Briefly, the phylogroup was established according to the PCR-based method developed by Clermont et al. (2013, 2019), which allows the rapid identification of the eight *E. coli* phylogroups belonging to *E. coli sensu stricto* (A, B1, B2, C, D, E, F, and G) (Supplementary Table S5). The clonotyping scheme utilizes the 489-nucleotide (nt) internal fragment of *fimH* (encoding the type 1 fimbrial adhesin) and the

469-nt internal *fumC* fragment retrieved from standard MLST (Weissman et al., 2012). Then, isolates of the prevalent clonotypes (CH) (determined in ≥ 3 isolates) were fully characterized by MLST following the Achtman scheme of seven genes (*adk*, *fumC*, *gyrB*, *icd*, *mdh*, *purA*, and *recA*) (Wirth et al., 2006) (Supplementary Table S6). Finally, CC131 *E. coli* were further typified by means of the virotyping scheme developed by Dahbi et al. (2014) based on the presence or absence of specific extraintestinal virulence factors, which differentiates 12 virotypes (A, B, C1, C2, C3, D1, D2, D3, D4, D5, E, and F) (Supplementary Tables S7, S8). Based on the characterization explained above, the identification of the high-risk lineages of *E. coli* was assigned according to the review of Manges et al. (2019), which defines the global 20 extraintestinal pathogenic *E. coli* (ExPEC) lineages, together with studies applying a comparable typification approach (Yamaji et al., 2018a, 2018b; Díaz-Jiménez et al., 2020).

2.7 Whole genome sequencing

ESBL-producing isolates belonging to CC131 were further investigated by whole genome sequencing (WGS). Briefly, DNA was extracted with the DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. After extraction, the DNA was quantified by an Invitrogen Qubit fluorimeter (Thermo Fisher Scientific, Massachusetts) and assessed for purity using a NanoDrop ND-1000 (Thermo Fisher Scientific, Massachusetts). The genomic DNA libraries for sequencing were prepared using the Nextera XT Library Prep kit (Illumina, CA, USA) according to the manufacturer's recommendation. Libraries were purified using the Mag-Bind RXN Pure Plus magnetic beads (Omega Biotek), following the instructions provided by the manufacturer. Then, libraries were pooled in equimolar amounts according to the quantification data provided by the Qubit dsDNA HS Assay (Thermo Fisher Scientific). Lastly, the libraries were sequenced in an Illumina NovaSeq PE150 platform, obtaining 100–150 bp paired-end reads, which were trimmed (Trim Galore 0.6.0) and filtered according to quality criteria (FastQC 0.11.9). The quality-filtered reads were assembled *de novo* using Unicycler (v0.4.8) (Wick et al., 2017), which uses an adapted SPAdes (v3.14.0) assembling algorithm (Bankevich et al., 2012). For the comprehensive typing of the isolates, the assembled contigs were analyzed using different bioinformatics tools available at the CGE webpage as specified and applying the thresholds suggested by default when required (minimum identity of 90% and coverage of 60%): SeroTypeFinder 2.0 (Joensen et al., 2015), CHTyper 1.0 (Roer et al., 2018), MobileElementFinder 1.03 (Johansson et al., 2021), PlasmidFinder 2.1, and pMLST 2.0 (Carattoli et al., 2014). For the phylogenetic typing, two different MLST schemes were applied: *E. coli* #1 (Wirth et al., 2006) and *E. coli* #2 (Jauregui et al., 2008). In addition to this typing, lineage-specific gene markers based on the sequence of CRISPRCasFinder software (<https://crisprcas.i2bc.paris-saclay.fr/>) were used to identify and type CRISPR and Cas systems within the genomes. ResFinder 4.1 was used for the identification of acquired genes and/or

chromosomal mutations mediating antimicrobial resistance (Camacho et al., 2009; Zankari et al., 2017; Bortolaia et al., 2020). The identification of acquired virulence genes was performed using the web-based tool VirulenceFinder 2.0 (Joensen et al., 2014; Tetzschner et al., 2020). In addition, the bacteria's pathogenicity towards human hosts was predicted through PathogenFinder 1.1 (Cosentino et al., 2013). Finally, the CSI phylogeny 1.4 tool (Call SNPs & Infer Phylogeny) was used to call, filter and infer a phylogeny based on the concatenated alignment of high-quality single-nucleotide polymorphisms (SNPs) within the core genome.

2.8 Statistical analysis

Comparisons of proportions were tested using a two-tailed Fisher's exact test. The *p*-values < 0.05 were considered statistically significant.

3 Results


3.1 Phylogeny, PCR screening of virulence traits and non-lactose fermenting isolates

Most of the cUTI isolates analyzed here belonged to the phylogroup B2 (111 of 154; 72.1%), and in turn, most B2 met the UPEC status (107 of 111; 96.4%). On the contrary, only 4 of the 43 (9.3%) non-B2 isolates (*p*-value < 0.05) showed carriage of ≥ 3 of the virulence traits genes associated with a higher efficiency in the colonization of the urinary tract (≥ 3 of *chuA*, *fyuA*, *vat*, and *yfcV* genes) (Spurbeck et al., 2012). The 43 non-B2 isolates showed six different phylogroups: B1 (14; 9.1%); D (9; 5.9%), A (8; 5.19%), E (6; 3.9%), C (4; 2.6%), and F (2; 1.3%).

The PCR screening of *rfbO25* and *fliC_{H4}* for the presumptive detection of the pandemic ST131 clonal group was positive in 30 and 29 isolates out of 154, respectively. Additionally, the flagellar-encoding gene *fliC_{H5}*, typically associated with NLF *E. coli* ST1193 or ST131 (CH40-41), was determined in 15 of the 24 NLF *E. coli* (24 of 154; 15.6%) (Supplementary Table S1).

3.2 Antimicrobial susceptibility testing and genotypic characterization of ESBL genes

The antimicrobial susceptibility testing (AST) of the 154 cUTI isolates showed the highest rates of resistance to ampicillin/amoxicillin (54.5%), ticarcillin (53.9%), and piperacillin (51.9%), followed by norfloxacin (47.4%), ciprofloxacin (32.5%), levofloxacin (32.5%), and amoxicillin-clavulanic acid (32.5%). Four isolates were categorized as colistin resistant by the MicroScan System; however, they were classified as susceptible by the standard broth microdilution (BMD) method (MICs < 0.25 mg/L). The PCR screening of *mcr* genes in those isolates gave a negative result, as well. Globally, 55 of the 154 cUTI (35.7%) isolates showed MDR, being *in vitro* resistant to ≥ 3 antimicrobial categories (Figure 1;



Supplementary Table S1). Isolates phenotypically suspected of being extended-spectrum cephalosporin resistant were further investigated by PCR for the presence of *bla*_{ESBL/AmpC} genes. As a result, *bla*_{CTX-M-15} and *bla*_{CTT} were determined in 12 and 1 isolates, respectively (Supplementary Table S1). Although the group of cUTI isolates positive for the UPEC status exhibited lower prevalence of MDR (38 of 111, 34.2%), the difference was not statistically significant in comparison with those negative for the UPEC status (17 of 43, 39.5%) (*p*-value = 0.58). It is important to note that most

of the FQR isolates (52 of 73; 71.2%) exhibited status UPEC; besides, 46 (63%) of 73 were MDR.

3.3 Clonal groups and workflow for the surveillance of fluoroquinolone resistance

A total of 81 out 154 cUTI *E. coli* were investigated for their clonotypes. The selection criterion for the 81 was to include isolates

TABLE 1 Prevalent clonotypes (≥ 3 isolates) within the 81 cUTI isolates positive for any of the surveillance traits proposed here, including FQR, O25b: H4, and H5-NLF isolates.

Clonotype (CH)	Phylogroup-ST (CC)	No. isolates (N=57)	UPEC status (N=44)	Non-lactose fermenting (N=21)	FQR (N=51)	MDR (N=32)
CH11-54	A-ST10 (CC10)	2	0	0	2	1
	A-ST744 (CC10)	1	0	0	1	0
CH65-32	B1-ST162 (CC469)	2	0	1	2	2
	B1-ST1431 (NONE)	2	0	0	2	0
CH40-20	B2-ST429 (CC429)	3	3	1	3	0
CH40-30	B2-ST131* (CC131)	19	19	3	16	12
CH40-22		4	4	0	3	0
CH40-41		4	4	2	4	2
CH14-64	B2-ST1193 (CC14)	10	9	10	10	8
CH13-106	B2-ST12 (CC12)	4	4	4	2	1
CH37-27	D-ST405 (CC405)	3	0	0	3	3
CH35-27	D-ST69 (CC69)	3	1	0	3	3


*In addition to ST131, the clonal group CC131 also appeared to be associated with ST9126. In total, the 33 CC131 isolates exhibited eight clonotypes: CH40-30 (19 isolates/16 FQR), CH40-41 (four isolates/four FQR), CH40-22 (four isolates/three FQR), CH1267-30 (two isolates/two FQR), CH40-27 (one isolate/zero FQR), CH40-331 (one isolate/one FQR), CH40-418 (one isolate/one FQR), and CH40-602 (one isolate/one FQR). UPEC, uropathogenic *E. coli*; FQR, fluoroquinolone resistant; MDR, multidrug resistant.

positive for any of the following traits associated with high-risk clones: FQR, carriers of *rfbO25* and *fliC_{H4}* genes, or being positive for H5-NLF. As a result, 29 different *fumC-fimH* (CH) combinations were established. Nevertheless, 10 CH combinations comprised 70.4% of the 81 isolates, which were fully characterized by MLST (Table 1; Supplementary Table S1). The main finding here is that both the pandemic clonal complex B2-CC131 and clonal group B2-ST1193 (CH14-64) comprised 28% of the 154 cUTI *E. coli* (33 and 10 isolates, respectively), and most importantly, they represented 52.1% of the FQR isolates. Other prevalent FQR clonal groups were D-ST69 (CH35-27), D-ST405 (CH37-27), and B2-ST429 (CH40-20), determined in three isolates each (Table 1). Figure 2 summarizes the workflow suggested for the surveillance of prevalent high-risk FQR clones and the main results obtained here.


As expected, all *E. coli* of ST1193 were NLF and also other 14 isolates, including the four representants of the high-risk clonal group B2-ST12 (CH13-106), or the B2-ST131 (CH40-30) and B2-ST131 (CH40-41) (three and two isolates, each respectively). It is also important to highlight the high diversity found within the 33 CC131 isolates, in terms of STs (131 and 9126) and clonotypes: CH40-30 (19 isolates/16 FQR), CH40-41 (four isolates/four FQR), CH40-22 (four isolates/three FQR), CH1267-30 (two isolates/two FQR), CH40-27 (one isolate/zero FQR), CH40-331 (one isolate/one FQR), CH40-418 (one isolate/one FQR), and CH40-602 (one isolate/one FQR) (Table 1). Except for the 4 ST131 (CH40-41) isolates, the remaining 29 CC131 were positive for *rfbO25* and *fliC_{H4}*. Finally, the *fliC_{H5}* was determined in all ST1193 isolates, in two out of four ST12, three of four ST131 (CH40-41), and one belonging to B2-ST404 (CH14-27) (Supplementary Table S1).

3.4 Molecular and *in silico* characterization of CC131 isolates

The CC131 isolates were molecularly characterized for the presence of specific virulence traits, whose result further corroborated the diversity within the clonal complex. Thus, 10 different virotypes were assigned to the 33 CC131: virotype C2 (seven isolates); virotypes A and E (five isolates each); virotype C3 (three isolates); virotypes C1, D3, and D5 (two isolates each); and virotypes D2, D4, and F (one isolate each). Additionally, the virulence profile of four CC131 remained non-typeable (NT). Of the 15 specific extraintestinal virulence factors included in the scheme of Dahbi et al. (2014), the secreted autotransporter toxin (*sat*), the K5 group II capsule (*kpsM* II-K5), and the P fimbriae associated with pyelonephritis together with the specific pilus tip adhesin molecule (*papEF* and *papG*) were the most prevalent (76%, 64%, and 30%, respectively). The co-occurrence of *papG*, *cnf1* (cytotoxic necrotizing factor 1), and *hlyA* (α -hemolysin) in eight isolates (24%) is also outstanding (Supplementary Table S8). Figure 3 represents the main traits of the 33 CC131 isolates, which mostly showed FQR (87.9%), and 12 (36.4%) were additionally ESBP-producers (CTX-M-15). The latter were whole genome sequenced and *in silico* analyzed using different bioinformatics tools of the Center for Genomic Epidemiology (CGE) (Supplementary Table S9). Thus, the SerotypeFinder tool confirmed O25b:H4 in all genomes. The 12



exhibited ST43, predicted by means of the alternative MLST scheme (ST#2) based on eight genes (*dinB*, *icdA*, *pabB*, *polB*, *putP*, *trpA*, *trpB*, and *uidA*). However, the MLST seven-gene scheme (ST#1) discriminated two STs (131 and 9126), and the core genome multi-locus typing (cgMLST) of 2,512 loci, differentiated the following 10 cgSTs: 7829 (for the two ST9126 isolates); 29126 (for two ST131 CH40-30 isolates); and 12614, 142625, 116708, 139233, 122338, 85838, 71301, and 13547 (one isolate, each). Regarding the resistome, the presence of *bla_{CTX-M-15}* gene was confirmed in the 12 CC131 genomes, which also showed the same set of chromosomal mutations conferring FQR (*gyrA* p.S83L, *gyrA* p.D87N, *parC* p.S80L, *parC* p.E84V, and *parE* p.I529L), consistent with the *in vitro* expression. As shown in Supplementary Table S9, most of the resistance genes were bracketed by different mobile genetic elements (MGEs), mainly insertion sequences, such as *ISEc9*, which was found with *bla_{CTX-M-15}* gene in six genomes. Furthermore, a wide range of extraintestinal virulence genes were predicted in the 12 genomes. The prediction of F4 (K88) fimbrial encoding genes *faeC*, *faeD*, *faeF*, *faeH*, and *faiE* associated with an *IS640* on contig 23 of



LREC-279 (ST9126) is outstanding because this is a typical fimbrial antigen of porcine enterotoxigenic *E. coli* (García-Meniño et al., 2021). Globally, the plasmidome analysis revealed not only the prevalent presence of IncF plasmids but also the high diversity of pMLST types represented by 10 different IncF formulae. In addition, six genomes showed carriage of small Col-like plasmids. The 12 ST131 genomes were predicted as human pathogen (probability >92%) by the PathogenFinder tool of the CGE. The genomic similarity of the 12 assemblies were further investigated through the SNP comparison of their core genome represented by 81.43% of the reference genome LREC-280 (size, 5.4Mb) using CSI phylogeny 1.4 (Figure 4; Supplementary Table S10). The phylogenetic dendrogram showed different subclusters. As expected, LREC-279 and LRC-285 (ST9126 and cgST7829) clustered with only 75 SNP differences. Likewise, the two cgST29126 (LREC-283 and LREC-284) showed 105 SNP differences. On the contrary, the LREC-288 exhibited the maximum distance of 487 SNPs with LREC-286.

4 Discussion

It is broadly accepted that UTIs are one of the most common and widespread community-acquired and nosocomial infections worldwide (Klein and Hultgren, 2020), constituting one of the leading causes of antibiotic prescriptions (Aabenhus et al., 2017). In addition, UTIs are also adding to the public health burden of infectious-related deaths, as recently reported in the systematic analysis for the Global Burden of Disease Study 2019 (Ikuta et al., 2022). Unfortunately, there are still no global harmonized protocols for the systematically monitoring of emerging successful FQ and cephalosporin-resistant clones implicated in this complex group of infections, which help to maintain the effectiveness of available treatment options.

Following our previous proposal on uUTI, based on a clonal diagnosis approach jointly with AST and the screening of predictor genes of uropathogenicity (García-Meniño et al., 2022), we addressed here the characterization of 154 non-duplicated *E. coli* recovered as the only pathogen involved in cases of cUTI. Our aim was to compare both syndromes in terms of the *E. coli* involved and to improve the surveillance protocol based on new observations. As a result, we found a similar phylogenetic distribution of the *E. coli* population implicated in uUTI or cUTI, being B2 the predominant phylogroup (67% and 72.1%, respectively), in line with its worldwide predominance in UTIs (Flament-Simon et al., 2020b; Lin et al., 2021). We also found a similar UPEC status prevalence within B2 (97% and 96.4%, respectively). No significant difference in the level of MDR was observed, either (30% vs. 35.7%); however, the AST showed important differences regarding the FQR (28% of uUTI vs. 47.4% of cUTI isolates; $p = 0.002$) and presence of ESBL producers (0% isolates in uUTI vs. 7.8% in cUTI; $p = 0.002$). Looking into the FQR clones implicated in UTI, we found a wide diversity of PG-CH combinations, some of them shared in both uUTI and cUTI, such as A (CH11-54), B1 (CH65-32), B2 (CH14-64), B2 (CH38-15), B2 (CH40-41), or D (CH37-27). While it is relevant that the FQR clone B2-ST1193 (CH14-64) exhibited similar implication in both studies (6% in uUTI and 6.5% in cUTI), it is also of note the higher prevalence and genetic diversity of the CC131 in cUTI isolates (33, 21.4%), from which 28 were FQR (18.2%) including 12 ESBL-producers (7.8%), vs. 6% CC131 in uUTI and only 2% FQR (García-Meniño et al., 2022).

MDR UPEC infections are globally associated with the major pandemic clonal lineages ST131 (CH40-H30R) and ST1193 (CH14-64), as the first and second most prevalent clones among FQ/cephalosporin-resistant *E. coli*, respectively (Colpan et al., 2013; Banerjee and Johnson, 2014; Pitout et al., 2022). Different studies assessed the success of the ST131 as a dominant pandemic ExPEC,




FIGURE 4

Phylogenetic dendrogram based on the SNP counts per substitution within the core genome of the 12 ESKAP ST131 isolates. The comparison of the WGS data sets resulting in a core genome represented by 81.43% of the reference genome LREC-280 (size, 5.4Mb). The tree was constructed with the CSI phylogeny version 1.4 (CGE, <https://cge.cbs.dtu.dk/services/CSIPhylogeny/>; parameters used for phylogenetic analysis: min. depth at SNP positions $\times 10$; min. relative depth at SNP positions: $\times 10$; min. distance between SNPs (prune): 10 bp; min. SNP quality: 30; min. read mapping quality: 25, a min. Z-score of 1.96 and by ignoring heterozygous SNPs). Values at each branch show the substitutions/site. The reference genome is highlighted in bold. The virotypes and IncF formulae of each isolate are indicated in red and blue, respectively.

linked with ESKAP-production and/or FQR (Banerjee and Johnson, 2014) and even, in some cases, with the carriage of carbapenemase- or colistin-resistance-encoding genes (Peirano et al., 2014; García-Meniño et al., 2018; Taati Moghadam et al., 2021). The clone B2-ST1193, with the O type 75, is another example of successful ExPEC. However, and despite the fact that it is already reported as an important contributor to the FQR across several countries, i.e., France (Birgy et al., 2020), Germany (Valenza et al., 2019), China (Ding et al., 2021), Korea (Kim et al., 2017), Vietnam (Nguyen et al., 2021), and the United States (Tchesnokova et al., 2019), it has been rarely identified in Spain (Flament-Simon et al., 2020b; García-Meniño et al., 2022; Becerra-Aparicio et al., 2023). Of note, the ST1193 isolates of the present study were recovered from patients between 38 and 85 years old. Here, the ST1193 was not associated with ESKAP production.

Regarding the ST131 pandemic lineage, its evolution over time is represented by three main clades (susceptible clades A and B and FQ/cephalosporin-resistant clade C), associated with different alleles of the fimbrial adhesion type 1 (*fimH*). The clade C (*fimH30*, clonotype CH40-30) is the most widely disseminated worldwide (Pitout and DeVinney, 2017). The CH40-30 FQR non-ESKAP-producing isolates are assigned to the subclade C1 (H30R), and those that, in addition to the FQR traits, also harbor the *bla*_{CTX-M-15} are classified within the subclade C2 (H30Rx). They are statistically associated with recurrent or persistent UTI and sepsis, and some authors have suggested that their success could be linked with their capacity of adaptation and sequential acquisition of virulence factors, FQR, and ESKAP production, in a context in which the use of FQ and cephalosporins is increasing globally (Banerjee and Johnson, 2014). According to the *fimH* type, the 31 ST131 of our study would be assigned to clades A (*fimH41*, four

isolates/four FQR), clade B (*fimH22*, four isolates/three FQR), and clade C (*fimH30*, 19 isolates/16 FQR/9 CTX-M15). The remaining ST131 possessed *fimH27* (one non-FQR isolate) and *fimH331*, *fimH418*, and *fimH602* (one FQR isolate each). The age range of the patients is striking, namely, between <1 year and 97 years old. Specifically, the two youngest, 8 months and 2 years old, presented isolates of the clonotypes CH40-30 and CH40-41 (FQR). The CC131 here was additionally represented by another clone, B2-ST9126 (CH1267-30), which is a very rare ST. In fact, there are only seven genomes uploaded in the Enterobase repository (as of November 2023; <https://enterobase.warwick.ac.uk/>), whose metadata refers to human origin, recovered in USA, Canada, and Spain (the two of the present study belonging to different cgST). Our ST9126 isolates were from two women of 64 and 87 years old.

On the other hand, it is well described that the evolution of the C1 and C2 subclades was strongly influenced by the acquisition and replacement of the specific plasmids, F1:A2:B20 and F2:A1:B-, that are predominant in those C1 (H30R) and C2 (H30Rx) subclades, respectively (Johnson et al., 2016; Mahéroult et al., 2019; Kondratyeva et al., 2020). Interestingly, we observed here a high diversity within the nine sequenced members of CC131-H30Rx subclade, carriers of different plasmid STs (F31:A4:B1, F4:A1:B20, F4:A-B10, F-A2:B-, F-A2:B20, F2:A1:B-, F29:A-B10, F36:A4:B1, and F31:A4:B1), where only one ST131 (CH40-30) showed the carriage of the predominant F2:A1:B- plasmid type. Taking as a reference previous studies/reviews (Nicolas-Chanoine et al., 2014), including those performed in our north-west health area of Spain (Mamani et al., 2019; Flament-Simon et al., 2020b; García-Meniño et al., 2022), it seems that a phylogenetic diversification within CC131 is currently accelerating. We could hypothesize the different origin of plasmid acquisition of these CC131 implicated in

cUTI; however, this assertion requires broader and deeper genomic analyses.

Previous studies performed in our country found different ESBL-producing *E. coli* prevalences in cUTIs. In a multicenter study, Merino et al. (2016) analyzed bacteremia episodes associated with UTIs ($n=425$) from eight hospitals from different Spanish geographical areas (2010–2011), and in a later work, Flament-Simon et al. (2020b) studied 100 non-duplicate *E. coli* consecutively obtained from different clinical samples, but mostly UTIs happened during 2016 in Spain. These authors reported a prevalence of 9.2% (39/425) and 6% (6/100) of ESBL-producing *E. coli*, respectively, which are similar values to the prevalence detected here (7.8%). Conversely, Becerra-Aparicio et al. (2023) reported a significant higher value (30.6%; 68/222) in *E. coli* isolates recovered from patients with healthcare-associated bacteremia of urinary origin from 12 Spanish tertiary hospitals (2017–2019). In agreement with our findings, most of the ESBL-producing isolates involved in UTIs, here and other countries, are associated with the pandemic ST131. Also in Spain, Flament-Simon et al. (2020a) found that 40.5% of 84 non-duplicated ESBL-producing *E. coli* causing UTIs were assigned to the CC131. This tendency was also reported by Merino et al. (2016) and Becerra-Aparicio et al. (2023), with prevalences of 54% (21/39) and 67.6% (46/68) of the ESBL-producing isolates assigned to ST131, respectively.

A difference found in our health area in comparison with other studies in Spain or other countries is regarding the subclade C1-M27 of ST131, which seems to be displacing the clade C2/CTX-M-15 in certain parts of the world, especially in Japan and Europe (Peirano and Pitout, 2019; Becerra-Aparicio et al., 2023). Our results suggest that C1-M27 is not yet disseminated in the health area of Oviedo, and the *bla*_{CTX-M-15} is still the predominant *bla* gene in Spain. Specifically, Flament-Simon et al. (2020a) reported a prevalence of 82.3% ($n: 28/34$) for the *bla*_{CTX-M-15} gene and 14.7% ($n: 5/34$) for the *bla*_{CTX-M-27}. In the study of Becerra-Aparicio et al. (2023), most of the isolates assigned to the C2/H30Rx subclone harbored the CTX-M-15 (37/44), and four belonged to the subclade C1-M27 (*bla*_{CTX-M-27}). All the divergences abovementioned with respect to the prevalence of the CC131 and ESBL-producing *E. coli* in Spain can be due to different factors, namely, i) a longer and higher exposition to last-line antibiotics of patients with healthcare-associated bacteremia of urinary origin compared to those that have not yet developed an invasive infection and ii) the specific epidemiological context in which the study is taking place.

In the guidelines on urological infections of the European Association of Urology (EAU) (European Association of Urology, 2023), there are specific recommendations for the treatment of cUTIs. Thus, the EAU recommends as a first-line therapy i) the amoxicillin in combination with aminoglycosides, ii) a second-generation cephalosporin also in combination with aminoglycosides, or iii) a third-generation cephalosporin intravenously in the case of patients with systemic symptoms. FQs are not automatically suitable as empirical antimicrobial therapy for cUTI. In fact, ciprofloxacin can be provided if the local resistance percentages are <10% only under certain circumstances (entire treatment given orally, in patients that do not require hospitalization or in patient that has an anaphylaxis for beta-

lactam antimicrobials). Finally, ciprofloxacin cannot be used as an empirical treatment in patients from urology departments or when patients have used fluoroquinolones in the last 6 months. The AST results obtained here with antimicrobial resistance prevalences of 54.5% ampicillin/amoxicillin, 12.3% gentamicin, 16.2% tobramycin, 5.2% amikacin, 12.3% cefuroxime, 8%–9% third-generation cephalosporin and 32.5–47.4% FQ, mean a serious therapeutic compromise for more than 10% of patients.

Specifically, the FQR found here is of great concern. FQ are included in the list of critically important antimicrobials for human medicine of the World Health Organization (WHO). The WHO also reports the worrisome prevalence of FQR among *E. coli* and global dissemination of FQR determinants within environmental, commensal, and pathogenic organisms (WHO, 2014; ECDC, 2022). The latest report from EFSA/ECDC (EFSA/ECDC, 2023) and recent studies indicate an increasing prevalence of FQR *E. coli* isolates in livestock animals, specifically among Shiga toxin-producing *E. coli* (STEC) and enterotoxigenic *E. coli* (ETEC) causing diarrhea in pigs increasing from 56.5% in 2005–2017 (García-Meniño et al., 2021) to reach up to 77% in the period 2020–2022 (García et al., 2022). Going beyond, we also investigated food-borne transmission of potentially UPEC in a parallel study (same period, 2020, and same health area, Oviedo), with a representative sampling of meat (pork, beef, chicken, and turkey) in different supermarkets. We found that 18% of the samples were carriers of *E. coli* FQR and 38% of ESBL-producing *E. coli*. Furthermore, we detected that 6% of the meat samples were carriers of *E. coli* positive for the status UPEC. Some of the meat isolates were further assayed in human bladder cells to prove a similar *in vitro* behavior for certain *E. coli* clones of animal origin positive for the UPEC status, compared to human UTI isolates, reinforcing the role of food-producing animals as a potential source of UPEC for consumers (García et al., 2023). This kind of studies, using the One Health approach, are a priority to understand the flow within the different hosts and ecosystems and to implement control measures.

In UPEC, resistance to FQ is significantly higher in the hospital setting in comparison with the community (Fasugba et al., 2015) and in developing countries (55.5%–85.5%) with respect to that in developed countries (5.1%–32.0%) (Kot, 2019). Specifically, in a multicenter study performed between 2013 and 2014 in Belgium, Germany, and Spain, the percentage of ciprofloxacin-resistant UPEC strains was 12.9%, 17.3%, and 39.8%, respectively (Kresken et al., 2016). Another study conducted in England showed that the rate of ciprofloxacin-resistant *E. coli* obtained from urine samples ranged between 15.5% and 20.4% (Abernethy et al., 2017). In the United States (2013–2014), 12.1% of the *E. coli* isolates from patients with acute uncomplicated and complicated pyelonephritis was resistant to ciprofloxacin (Talan et al., 2016), and a 5.1% was detected between 2016 and 2017 from the urine samples of patients with UTI (Yamaji et al., 2018b). As mentioned before, in our collection, the rate of resistance against different FQ is remarkably higher in comparison with these studies.

Mutations in several genes targeting serine residues in DNA gyrase (GyrA-S83L) and topoisomerase IV (ParC-S80I) and a common combination with an overall deleterious mutation in

GyrA-D87N can lead to resistance development against FQ. Another mechanism of resistance is the acquisition of specific plasmid-mediated quinolone resistance (PMQR) *qnr* genes, which are commonly located on mobile-resistant elements (Poirel et al., 2005). The emerging lineages ST131-H30R and ST1193 are, nowadays, playing the prominent role in the dissemination and maintenance of FQR. In the ST131 genomes here analyzed and in ST1193 genomes of a previously published paper (García-Meniño et al., 2022), the presence of *qnr* genes is scarce (predicted in 1 out of the 12 ST131 genomes; LREC-281) or null, respectively. The transmission of these resistances is then mainly linked to chromosomal point mutations transmitted vertically in these relevant lineages (Price et al., 2013; Johnson et al., 2018), while *qnr* genes are not playing a major role. On the other hand, it is suggested that the sequential acquisition of double serine quinolone-resistant determining region mutations (QRDR) (GyrA-S83L and ParC-S80I), typically presented in these predominant MDR clonal groups of *E. coli* (Pitout et al., 2022), as we proved in our cUTI and uUTI collections, has been probably a key driver behind the success of the pandemic dissemination of these clones in the last few decades (Tchesnokova et al., 2023). Thus, the 12 FQR ST131 sequenced here showed the common set of mutations (*gyrA* p.S83L, *gyrA* p.D87N, *parC* p.S80I, *parC* p.E84V, and *parE* p.I529L), and the ST1193 genomes analyzed in the previous study exhibited the same FQR pattern (*gyrA* p.S83L, *gyrA* p.D87N, *parC* p.S80I, and *parE* p.L416F) (García-Meniño et al., 2022), in both cases correlating with the *in vitro* expression. Furthermore, the QRDR point mutations would be generating a fitness benefit, which would explain why the bacteria keep them. Therefore, the substantial reduction in the prescription of FQ in the recent decade is not significantly generating a decrease in the percentage of FQR or decrease in the circulation of these MDR clones (Tchesnokova et al., 2023). In addition to the energetically favorable QRDR mutations, the carriage of low-cost plasmids and integrons with weak promoters and some virulence factors (colonization-associated genes) may have also a fitness-favorable impact in these clones (Fuzy and Sokurenko, 2023). On the other hand, the need of an appropriate genetic background exposed by the selective epistasis hypothesis would explain why other *E. coli* strains with the same set of QRDR mutation could not achieve the same level of notoriety (Cummins et al., 2021; Fuzy and Sokurenko, 2023). In this context, the spread of highly successful clones that manifest an adaptive advantage with respect to other clones, and with capacity of colonization, currently represents a serious sanitary issue despite a reduction in antibiotic pressure.

5 Conclusions

The global MDR high-risk clones of *E. coli* CC131 and ST1193 represent a challenge for the treatment of cUTIs in our health area,

since 52% of the FQR isolates analyzed here belonged to these lineages. Although *E. coli* CC131 and ST1193 are also involved in the community uUTIs of this geographic area, the differences in prevalence and resistance background would be explained by a lower exposure to antibiotic treatments. Interventions to eradicate these specific FQR clones, such as the design of vaccines against them, along with surveillance for other emerging ones, are essential for antibiotic use optimization programs. Based on our results, we suggest some key traits for a lab workflow monitoring of cUTIs. Thus, a non-lactose fermenting screening, together with the detection of O25b (*rfbO25b*), H4 (*fliC_{H4}*), and H5 (*fliC_{H5}*) genes, and phylogroup and clonotyping assignation, is a reasonable approach that can be easily implemented for the surveillance of successful and emerging *E. coli* high-risk clones associated with FQR spread in cUTIs, such as the uncommonly reported O25b:H4-B2-ST9126 (CH1267-30) of the CC131.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: <https://www.ebi.ac.uk/ena>, ERS12564407 to ERS12564418.

Ethics statement

The studies involving humans were approved by the Comité de Ética de la investigación con medicamentos del Principado de Asturias, Hospital Universitario Central de Asturias (Spain), with code CEImPA 2021.531. The studies were conducted in accordance with the local legislation and institutional requirements. The human samples used in this study were acquired from primarily isolated as part of our previous study for which ethical approval was obtained. Written informed consent for participation was not required from the participants or the participants' legal guardians/next of kin in accordance with the national legislation and institutional requirements.

Author contributions

IG-M: Formal analysis, Investigation, Methodology, Software, Validation, Visualization, Writing – original draft. VG: Formal analysis, Methodology, Software, Writing – original draft, Validation, Visualization. PL: Methodology, Software, Validation, Visualization, Writing – original draft. JF: Formal analysis, Funding acquisition, Investigation, Project administration, Validation, Visualization, Writing – review & editing. AM: Conceptualization, Formal analysis, Funding acquisition, Investigation, Project

administration, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by the projects PID2019-104439RB-C21 and PID2022-143041OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by FEDER Una manera de hacer Europa; FIS PI17-00728 (Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Spain), co-funded by ERDF; ED431C 2021/11 from the Consellería de Cultura, Educación e Ordenación Universitaria (Xunta de Galicia) and ERDF; GRUPIN IDI/2022/000033 by the Regional Ministry of Science of Asturias (IDI/2022/000033). IG-M and VG acknowledge the Consellería de Cultura, Educación e Ordenación Universitaria, Xunta de Galicia for their post-doctoral grants (Grant Number ED481B-2021-006 and ED481-D2022/012, respectively). The Research stay of IG-M at the Hospital Universitario Central de Asturias was funded by a grant from the Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC).

References

- Aabenhus, R., Hansen, P., Siersma, V., and Bjerrum, L. (2017). Clinical indications for antibiotic use in Danish general practice: results from a nationwide electronic prescription database. *Scandinavian J. Primary Health Care* 35:2, 162–169. doi: 10.1080/02813432.2017.1333321
- Abernethy, J., Guy, R., Sheridan, E. A., Hopkins, S., Kiernan, M., Wilcox, M. H., et al. (2017). Epidemiology of *Escherichia coli* bacteraemia in England: results of an enhanced sentinel surveillance programme. *J. Hosp. Infect.* 95, 365–375. doi: 10.1016/j.jhin.2016.12.008
- Aydin, A., Ahmed, K., Zaman, I., Khan, M. S., and Dasgupta, P. (2015). Recurrent urinary tract infections in women. *Int. Urogynecol. J.* 26, 795–804. doi: 10.1007/s00192-014-2569-5
- Banerjee, R., and Johnson, J. R. (2014). A new clone sweeps clean: the enigmatic emergence of *Escherichia coli* sequence type 131. *Antimicrob. Agents Chemother.* 58, 4997–5004. doi: 10.1128/AAC.02824-14
- Bankevich, A., Nurk, S., Antipov, D., Gurevich, A. A., Dvorkin, M., Kulikov, A. S., et al. (2012). SPAdes: A new genome assembly algorithm and its applications to single-cell sequencing. *Journal of Computational Biology*. 19, 455–477. doi: 10.1089/cmb.2012.0021
- Becerra-Aparicio, F., Gómez-Zorrilla, S., Hernández-García, M., Gijón, D., Siverio, A., Berbel, D., et al. (2023). Significant increase of CTX-M-15-ST131 and emergence of CTX-M-27-ST131 *Escherichia coli* high-risk clones causing healthcare-associated bacteraemia of urinary origin in Spain (ITUBRAS-2 project). *J. Antimicrob. Chemother.* 78, 2291–2296. doi: 10.1093/jac/dkac234
- Bortolaia, V., Kaas, R. S., Ruppe, E., Roberts, M. C., Schwarz, S., Cattoir, V., et al. (2020). ResFinder 4.0 for predictions of phenotypes from genotypes. *J. Antimicrob. Chemother.* 75, 3491–3500. doi: 10.1093/jac/dkaa345
- Camacho, C., Coulouris, G., Avagyan, V., Ma, N., Papadopoulos, J., Bealer, K., et al. (2009). BLAST+: architecture and applications. *BMC Bioinf.* 10, 421. doi: 10.1186/1471-2105-10-421
- Carattoli, A., Zankari, E., García-Fernández, A., Voldby Larsen, M., Lund, O., Villa, L., et al. (2014). In silico detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing. *Antimicrob. Agents Chemother.* 58, 3895–3903. doi: 10.1128/AAC.02412-14
- Clermont, O., Christenson, J. K., Denamur, E., and Gordon, D. M. (2013). The Clermont *Escherichia coli* phylo-typing method revisited: Improvement of specificity and detection of new phylo-groups. *Environ. Microbiol. Rep.* 5, 58–65. doi: 10.1111/1758-2229.12019
- Clermont, O., Dixit, O. V. A., Vangchhia, B., Condamine, B., Dion, S., Briider-Nahmias, A., et al. (2019). Characterization and rapid identification of phylogroup G in *Escherichia coli*, a lineage with high virulence and antibiotic resistance potential. *Environ. Microbiol.* 21, 3107–3117. doi: 10.1111/1462-2920.14713
- Colpan, A., Johnston, B., Porter, S., Clabots, C., Anway, R., Thao, L., et al. (2013). *Escherichia coli* sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among US veterans. *Clin. Infect. Dis.* 57, 1256–1265. doi: 10.1093/cid/cit503
- Cosentino, S., Voldby Larsen, M., Møller Aarestrup, F., and Lund, O. (2013). PathogenFinder—distinguishing friend from foe using bacterial whole genome sequence data. *PLoS One* 8 (10), e77302. doi: 10.1371/annotation/b84e1af7-c127-45c3-be22-76abd977600f
- Cummins, E. A., Snaith, A. E., McNally, A., and Hall, R. J. (2021). The role of potentiating mutations in the evolution of pandemic *Escherichia coli* clones. *Eur. J. Clin. Microbiol. Infect. Dis.* doi: 10.1007/s10096-021-04359-3
- Dahbi, G., Mora, A., Mamani, R., López, C., Alonso, M. P., Marzoa, J., et al. (2014). Molecular epidemiology and virulence of *Escherichia coli* O16:H5-ST131: comparison with H30 and H30-Rx subclones of O25b:H4-ST131. *Int. J. Med. Microbiol.* 304, 1247–1257. doi: 10.1016/j.ijmm.2014.10.002
- Díaz-Jiménez, D., García-Meniño, I., Fernández, J., García, V., and Mora, A. (2020). Chicken and Turkey meat: Consumer exposure to multidrug-resistant Enterobacteriaceae including mcr-carriers, uropathogenic *E. coli* and high-risk lineages such as ST131. *Int. J. Food Microbiol.* 331, 108750. doi: 10.1016/j.jifoodmicro.2020.108750
- Ding, Y., Zhang, J., Yao, K., Gao, W., and Wang, Y. (2021). Molecular characteristics of the new emerging global clone ST1193 among clinical isolates of *Escherichia coli* from neonatal invasive infections in China. *Eur. J. Clin. Microbiol. Infect. Dis.* 40, 833–840. doi: 10.1007/s10096-020-04079-0
- ECDC (2022). *Antimicrobial resistance surveillance in Europe 2022 - 2020 data* (Copenhagen: WHO Regional Office for Europe).
- EFSA/ECDC (2023). The European Union Summary Report on Antimicrobial Resistance in zoonotic and indicator bacteria from humans, animals and food in 2020/2021. *EFSA J. Eur. Food Saf. Auth.* 21 (3), 7867. doi: 10.2903/J.EFSA.2023.7867
- European Association of Urology (2023). *EAU guidelines on Urological Infections* (Arnhem, The Netherlands: Eur. Assoc. Urol).
- Fasugba, O., Gardner, A., Mitchell, B. G., and Mnataganian, G. (2015). Ciprofloxacin resistance in community- and hospital-acquired *Escherichia coli* urinary tract infections: a systematic review and meta-analysis of observational studies. *BMC Infect. Dis.* 15, 545. doi: 10.1186/s12879-015-1282-4
- Flament-Simon, S.-C., García, V., Duprilot, M., Mayer, N., Alonso, M. P., García-Meniño, I., et al. (2020a). High prevalence of ST131 subclades C2-H30Rx and C1-M27

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fcimb.2024.1351618/full#supplementary-material>

among extended-spectrum β -lactamase-producing *Escherichia coli* causing human extraintestinal infections in patients from two hospitals of Spain and France during 2015. *Front. Cell. Infect. Microbiol.* 10. doi: 10.3389/fcimb.2020.00125

Flament-Simon, S.-C., Nicolas-Chanoine, M.-H., García, V., Duprilot, M., Mayer, N., Alonso, M. P., et al. (2020b). Clonal Structure, Virulence Factor-encoding Genes and Antibiotic Resistance of *Escherichia coli*, Causing Urinary Tract Infections and Other Extraintestinal Infections in Humans in Spain and France during 2016. *Antibiotics* 9, 161. doi: 10.3390/antibiotics9040161

Flores-Mireles, A. L., Walker, J. N., Caparon, M., and Hultgren, S. J. (2015). Urinary tract infections: epidemiology, mechanisms of infection and treatment options. *Nat. Rev. Microbiol.* 13, 269. doi: 10.1038/nrmicro3432

Foxman, B. (2003). Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. *Dis. Mon* 49, 53–70. doi: 10.1067/mda.2003.7

Foxman, B. (2010). The epidemiology of urinary tract infection. *Nat. Rev. Urol.* 7, 653–660. doi: 10.1038/nrurol.2010.190

Foxman, B. (2014). Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. *Infect. Dis. Clin. North Am.* 28, 1–13. doi: 10.1016/j.idc.2013.09.003

Fuzi, M., and Sokurenko, E. (2023). Commensal fitness advantage may contribute to the global dissemination of multidrug-resistant lineages of bacteria—the case of uropathogenic *E. coli*. *Pathog. (Basel Switzerland)* 12, 1150. doi: 10.3390/pathogens12091150

García, V., García-Meniño, I., Gómez, V., Jiménez-Orellana, M., Méndez, A., Aguarón, A., et al. (2022). Mobile colistin resistance (MCR), extended-spectrum beta-lactamase (ESBL) and multidrug resistance monitoring in *Escherichia coli* (commensal and pathogenic) in pig farming: need of harmonized guidelines and clinical breakpoints. *Front. Microbiol.* 13. doi: 10.3389/fmicb.2022.1042612

García, V., Lestón, L., Parga, A., García-Meniño, I., Fernández, J., Otero, A., et al. (2023). Genomics, biofilm formation and infection of bladder epithelial cells in potentially uropathogenic *Escherichia coli* (UPEC) from animal sources and human urinary tract infections (UTIs) further support food-borne transmission. *One Heal. (Amsterdam Netherlands)* 16, 100558. doi: 10.1016/j.onehlt.2023.100558

García-Meniño, I., García, V., Alonso, M. P., Blanco, J. E., Blanco, J., and Mora, A. (2021). Clones of enterotoxigenic and Shiga toxin-producing *Escherichia coli* implicated in swine enteric colibacillosis in Spain and rates of antibiotic resistance. *Vet. Microbiol.* 252, 108924. doi: 10.1016/j.vetmic.2020.108924

García-Meniño, I., García, V., Mora, A., Díaz-Jiménez, D., Flament-Simon, S. C., Alonso, M. P., et al. (2018). Swine enteric colibacillosis in Spain: Pathogenic potential of mcr-1 ST10 and ST131 *E. coli* isolates. *Front. Microbiol.* 9. doi: 10.3389/fmicb.2018.02659

García-Meniño, I., Lumberreras, P., Lestón, L., Álvarez-Álvarez, M., García, V., Hammerl, J. A., et al. (2022). Occurrence and genomic characterization of clone ST1193 clonotype 14-64 in uncomplicated urinary tract infections caused by *Escherichia coli* in Spain. *Microbiol. Spectr.* 10, e00041-22. doi: 10.1128/spectrum.00041-22

García-Meniño, I., Lumberreras, P., Villedor, P., Díaz-Jiménez, D., Lestón, L., Fernández, J., et al. (2020). Comprehensive Statistical Evaluation of Etest®, UMIC®, MicroScan and Disc Diffusion versus Standard Broth Microdilution: Workflow for an Accurate Detection of Colistin-Resistant and MCR-Positive *E. coli*. *Antibiotics* 9 (12), 861. doi: 10.3390/antibiotics9120861

Gupta, K., Hooton, T. M., Nabar, K. G., Wullt, B., Colgan, R., Miller, L. G., et al. (2011). International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. *Clin Infect Dis.* 52, e103-20–e120. doi: 10.1093/cid/ciq257

Ikuta, K. S., Swetschinski, L. R., Robles Aguilar, G., Sharara, F., Mestrovic, T., Gray, A. P., et al. (2022). Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet* 400, 2221–2248. doi: 10.1016/S0140-6736(22)02185-7

Jauregui, F., Landraud, L., Passet, V., Diancourt, L., Frapy, E., Guigon, G., et al. (2008). Phylogenetic and genomic diversity of human bacteremic *Escherichia coli* strains. *BMC Genomics* 9, 560. doi: 10.1186/1471-2164-9-560

Joensen, K. G., Scheut, F., Lund, O., Hasman, H., Kaas, R. S., Nielsen, E. M., et al. (2014). Real-time whole-genome sequencing for routine typing, surveillance, and outbreak detection of verotoxigenic *Escherichia coli*. *J. Clin. Microbiol.* 52, 1501–1510. doi: 10.1128/JCM.03617-13

Joensen, K. G., Tetzschner, A. M. M., Iguchi, A., Aarestrup, F. M., and Scheut, F. (2015). Rapid and easy in silico serotyping of *Escherichia coli* isolates by use of whole-genome sequencing data. *J. Clin. Microbiol.* 53, 2410–2426. doi: 10.1128/JCM.00008-15

Johansson, M. H. K., Bortolaia, V., Tansirichaiya, S., Aarestrup, F. M., Roberts, A. P., and Petersen, T. N. (2021). Detection of mobile genetic elements associated with antibiotic resistance in *Salmonella enterica* using a newly developed web tool: MobileElementFinder. *J. Antimicrob. Chemother.* 76, 101–109. doi: 10.1093/jac/dkaa390

Johnson, T. J., Danzeisen, J. L., Youmans, B., Case, K., Llop, K., Munoz-Aguayo, J., et al. (2016). Separate F-type plasmids have shaped the evolution of the H30 subclone of *Escherichia coli* sequence type 131. *mSphere* 1, 10.1128/msphere.00121-16. doi: 10.1128/msphere.00121-16

Johnson, T. J., Elnekave, E., Miller, E. A., Munoz-Aguayo, J., Figueroa, C. F., Johnston, B., et al. (2018). Phylogenomic analysis of extraintestinal pathogenic *Escherichia coli* sequence type 1193, an emerging multidrug-resistant clonal group. *Antimicrob. Agents Chemother.* 63, 10.1128/aac.01913-18. doi: 10.1128/AAC.01913-18

Kim, Y., Oh, T., Nam, Y. S., Cho, S. Y., and Lee, H. J. (2017). Prevalence of ST131 and ST1193 among bloodstream isolates of *Escherichia coli* not susceptible to ciprofloxacin in a tertiary care university hospital in Korea 2013–2014. *Clin. Lab.* 63, 1541–1543. doi: 10.7754/Clin.Lab.2017.170319

Klein, R. D., and Hultgren, S. J. (2020). Urinary tract infections: microbial pathogenesis, host-pathogen interactions and new treatment strategies. *Nat. Rev. Microbiol.* 18, 211. doi: 10.1038/s41579-020-0324-0

Klevens, R. M., Edwards, J. R., Richards, C. L. Jr, Horan, T. C., Gaynes, R. P., Pollock, D. A., et al. (2007). Estimating health care-associated infections and deaths in U.S. hospitals 2002. *Public Health Rep.* 122, 160–166. doi: 10.1177/00335490712200205

Kondratyeva, K., Salmon-Divon, M., and Navon-Venezia, S. (2020). Meta-analysis of pandemic *Escherichia coli* ST131 plasmidome proves restricted plasmid-clade associations. *Sci. Rep.* 10, 1–11. doi: 10.1038/s41598-019-56763-7

Kot, B. (2019). Antibiotic resistance among uropathogenic *Escherichia coli*. *Polish J. Microbiol.* 68, 403. doi: 10.33073/pjm-2019-048

Kresken, M., Körber-Irrgang, B., Biedenbach, D. J., Batista, N., Besard, V., Cantón, R., et al. (2016). Comparative *in vitro* activity of oral antimicrobial agents against Enterobacteriaceae from patients with community-acquired urinary tract infections in three European countries. *Clin. Microbiol. Infect.* 22, 63.e1–63.e5. doi: 10.1016/j.cmi.2015.08.019

Lin, W. H., Zhang, Y. Z., Liu, P. Y., Chen, P. S., Wang, S. N., Kuo, P. Y., et al. (2021). Distinct Characteristics of *Escherichia coli* Isolated from Patients with Urinary Tract Infections in a Medical Center at a Ten-Year Interval. *Pathog. (Basel Switzerland)* 10, 1156. doi: 10.3390/pathogens10091156

MacVane, S. H., Tuttle, L. O., and Nicolau, D. P. (2015). Demography and burden of care associated with patients readmitted for urinary tract infection. *J. Microbiol. Immunol. Infect.* 48, 517–524. doi: 10.1016/j.jmii.2014.04.002

Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., et al. (2012). Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin. Microbiol. Infect.* 18, 268–281. doi: 10.1111/j.1469-0691.2011.03570.x

Mahéault, A. C., Kemble, H., Magnan, M., Gachet, B., Roche, D., Nagard, H., et al. (2019). Advantage of the F2A1:B- IncF Pandemic Plasmid over IncC Plasmids in *In Vitro* Acquisition and Evolution of blaCTX-M Gene-Bearing Plasmids in *Escherichia coli*. *Antimicrob. Agents Chemother.* 63, 10.1128/aac.01130-19. doi: 10.1128/AAC.01130-19

Mamani, R., Flament-Simon, S. C., García, V., Mora, A., Alonso, M. P., López, C., et al. (2019). Sequence types, clonotypes, serotypes, and virotypes of extended-spectrum β -lactamase-producing *Escherichia coli* causing bacteraemia in a Spanish hospital over a 12-year period, (2000 to 2011). *Front. Microbiol.* 10. doi: 10.3389/fmicb.2019.01530

Manges, A. R., Geum, H. M., Guo, A., Edens, T. J., Fibke, C. D., and Pitout, J. D. D. (2019). Global extraintestinal pathogenic *Escherichia coli* (ExPEC) lineages. *Clin. Microbiol. Rev.* 32, e00135-18. doi: 10.1128/CMR.00135-18

Medina, M., and Castillo-Pino, E. (2019). An introduction to the epidemiology and burden of urinary tract infections. *Ther. Adv. Urol.* 11, 1756287219832172. doi: 10.1177/1756287219832172

Merino, I., Shaw, E., Horcajada, J. P., Cercenado, E., Mirelis, B., Pallarés, M. A., et al. (2016). CTX-M-15-H30Rx-ST131 subclone is one of the main causes of healthcare-associated ESBL-producing *Escherichia coli* bacteraemia of urinary origin in Spain. *J. Antimicrob. Chemother.* 71, 2125–2130. doi: 10.1093/jac/dkw133

Murray, C. J., Ikuta, K. S., Sharara, F., Swetschinski, L., Robles Aguilar, G., Gray, A., et al. (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet* 399, 629–655. doi: 10.1016/S0140-6736(21)02724-0

Nguyen, Q., Nguyen, T. T. N., Pham, P., Chau, V., Nguyen, L. P. H., Nguyen, T. D., et al. (2021). Genomic insights into the circulation of pandemic fluoroquinolone-resistant extra-intestinal pathogenic *Escherichia coli* ST1193 in Vietnam. *Microb. Genomics* 7 (12), 000733. doi: 10.1099/mgen.0.000733

Nicolas-Chanoine, M. H., Bertrand, X., and Madec, J. Y. (2014). *Escherichia coli* ST131, an intriguing clonal group. *Clin. Microbiol. Rev.* 27, 543–574. doi: 10.1128/CMR.00125-13

Peirano, G., Bradford, P. A., Kazmierczak, K. M., Badal, R. E., Hackel, M., Hoban, D. J., et al. (2014). Global incidence of carbapenemase-producing *Escherichia coli* ST131. *Emerg. Infect. Dis.* 20, 1928. doi: 10.3201/eid2011.141388

Peirano, G., and Pitout, J. D. D. (2019). Extended-spectrum β -lactamase-producing enterobacteriaceae: update on molecular epidemiology and treatment options. *Drugs* 79, 1529–1541. doi: 10.1007/s40265-019-01180-3

Pitout, J. D., and DeVinney, R. (2017). *Escherichia coli* ST131: a multidrug-resistant clone primed for global domination. *F1000Res* 6, F1000 Faculty Rev-195. doi: 10.12688/f1000research.10609.1

Pitout, J. D. D., Peirano, G., Chen, L., DeVinney, R., and Matsumura, Y. (2022). *Escherichia coli* ST1193: Following in the Footsteps of *E. coli* ST131. *Antimicrob. Agents Chemother* 66, e00511-22. doi: 10.1128/AAC.00511-22

- Poirel, L., Rodriguez-Martinez, J. M., Mammeri, H., Liard, A., and Nordmann, P. (2005). Origin of plasmid-mediated quinolone resistance determinant QnrA. *Antimicrob. Agents Chemother.* 49, 3523–3525. doi: 10.1128/AAC.49.8.3523-3525.2005
- Price, L. B., Johnson, J. R., Aziz, M., Clabots, C., Johnston, B., Tchesnokova, V., et al. (2013). The epidemic of extended-spectrum- β -lactamase-producing *Escherichia coli* ST131 is driven by a single highly pathogenic subclone, H30-Rx. *MBio* 4. doi: 10.1128/mBio.00377-13
- Roer, L., Johannesen, T. B., Hansen, F., Stegger, M., Tchesnokova, V., Sokurenko, E., et al. (2018). CHTyper, a Web Tool for Subtyping of Extraintestinal Pathogenic *Escherichia coli* Based on the *fumC* and *fimH* Alleles. *J. Clin. Microbiol.* 56, e00063–e00018. doi: 10.1128/JCM.00063-18
- Spurbeck, R. R., Dinh, P. C., Walk, S. T., Stapleton, A. E., Hooton, T. M., Nolan, L. K., et al. (2012). *Escherichia coli* Isolates That Carry *vat*, *fyuA*, *chuA*, and *yfcV* Efficiently Colonize the Urinary Tract. *Infect. Immun.* 80, 4115–4122. doi: 10.1128/IAI.00752-12
- Taati Moghadam, M., Mirzaei, M., Fazel Tehrani Moghaddam, M., Babakhani, S., Yeganeh, O., Asgharzadeh, S., et al. (2021). The challenge of global emergence of novel colistin-resistant *Escherichia coli* ST131. *Microb. Drug Resist.* 27(11), 1513–1524. doi: 10.1089/MDR.2020.0505
- Talan, D. A., Takhar, S. S., Krishnadasan, A., Abrahamian, F. M., Mower, W. R., and Moran, G. J. (2016). Fluoroquinolone-resistant and extended-spectrum β -lactamase-producing *Escherichia coli* infections in patients with pyelonephritis, United States. *Emerg. Infect. Dis.* 22, 1594. doi: 10.3201/eid2209.160148
- Tchesnokova, V., Larson, L., Basova, I., Sledneva, Y., Choudhury, D., Heng, J., et al. (2023). Increase in the Rate of Gut Carriage of Fluoroquinolone-Resistant *Escherichia coli* despite a Reduction in Antibiotic Prescriptions. *Res. Sq* 3, 110. doi: 10.21203/rs.3.rs-2426668/v1
- Tchesnokova, V. L., Rechkina, E., Larson, L., Ferrier, K., Weaver, J. L., Schroeder, D. W., et al. (2019). Rapid and extensive expansion in the United States of a new multidrug-resistant *Escherichia coli* clonal group, sequence type 1193. *Clin. Infect. Dis.* 68, 334–337. doi: 10.1093/cid/ciy525
- Tetzschner, A. M. M., Johnson, J. R., Johnston, B. D., Lund, O., and Scheutz, F. (2020). In silico genotyping of *Escherichia coli* isolates for extraintestinal virulence genes by use of whole-genome sequencing data. *J. Clin. Microbiol.* 58, 10.1128/jcm.01269-20. doi: 10.1128/JCM.01269-20
- Valenza, G., Werner, M., Eisenberger, D., Nickel, S., Lehner-Reindl, V., Höller, C., et al. (2019). First report of the new emerging global clone ST1193 among clinical isolates of extended-spectrum β -lactamase (ESBL)-producing *Escherichia coli* from Germany. *J. Glob. Antimicrob. Resist.* 17, 305–308. doi: 10.1016/j.jgar.2019.01.014
- Weissman, S. J., Johnson, J. R., Tchesnokova, V., Billig, M., Dykhuizen, D., Riddell, K., et al. (2012). High-resolution two-locus clonal typing of extraintestinal pathogenic *Escherichia coli*. *Appl. Environ. Microbiol.* 78, 1353–1360. doi: 10.1128/AEM.06663-11
- WHO (2014). *Antimicrobial resistance: global report on surveillance* WHO/HSE/PED/AIP/2014.2. (Geneva, Switzerland: WHO Document Production Services).
- Wick, R. R., Judd, L. M., Gorrie, C. L., and Holt, K. E. (2017). Unicycler: Resolving bacterial genome assemblies from short and long sequencing reads. *PLoS Comput. Biol.* 13, e1005595. doi: 10.1371/journal.pcbi.1005595
- Wirth, T., Falush, D., Lan, R., Colles, F., Mensa, P., Wieler, L. H., et al. (2006). Sex and virulence in *Escherichia coli*: an evolutionary perspective. *Mol. Microbiol.* 60, 1136–1151. doi: 10.1111/j.1365-2958.2006.05172.x
- Yamaji, R., Friedman, C. R., Rubin, J., Suh, J., Thys, E., McDermott, P., et al. (2018a). A population-based surveillance study of shared genotypes of *Escherichia coli* isolates from retail meat and suspected cases of urinary tract infections. *mSphere* 3 (4), e00179-18. doi: 10.1128/mSphere.00179-18
- Yamaji, R., Rubin, J., Thys, E., Friedman, C. R., and Riley, L. W. (2018b). Persistent pandemic lineages of uropathogenic *Escherichia coli* in a college community from 1999 to 2017. *J. Clin. Microbiol.* 56 (4), e01834-17. doi: 10.1128/JCM.01834-17
- Zankari, E., Allesøe, R., Joensen, K. G., Cavaco, L. M., Lund, O., and Aarestrup, F. M. (2017). PointFinder: a novel web tool for WGS-based detection of antimicrobial resistance associated with chromosomal point mutations in bacterial pathogens. *J. Antimicrob. Chemother.* 72, 2764–2768. doi: 10.1093/jac/dkx217->